Pepaxto: A New Peptide-Drug Conjugate for Heavily Pretreated Relapsed and Refractory Multiple Myeloma.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Pepaxto: A New Peptide-Drug Conjugate for Heavily Pretreated Relapsed and Refractory Multiple Myeloma.
- Published In:
- The Annals of pharmacotherapy, 56(8), 951-957 (2022)
- Authors:
- Jessee, Jeremiah K
- Database ID:
- RPEP-06227
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-06227APA
Jessee, Jeremiah K. (2022). Pepaxto: A New Peptide-Drug Conjugate for Heavily Pretreated Relapsed and Refractory Multiple Myeloma.. The Annals of pharmacotherapy, 56(8), 951-957. https://doi.org/10.1177/10600280211058388
MLA
Jessee, Jeremiah K. "Pepaxto: A New Peptide-Drug Conjugate for Heavily Pretreated Relapsed and Refractory Multiple Myeloma.." The Annals of pharmacotherapy, 2022. https://doi.org/10.1177/10600280211058388
RethinkPeptides
RethinkPeptides Research Database. "Pepaxto: A New Peptide-Drug Conjugate for Heavily Pretreated..." RPEP-06227. Retrieved from https://rethinkpeptides.com/research/jessee-2022-pepaxto-a-new-peptidedrug
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.